Drug interactions and antiretroviral drug monitoring

Matthew Foy, C. John Sperati, Gregory M. Lucas, Michelle M. Estrella

Research output: Contribution to journalArticle

Abstract

Owing to the improved longevity afforded by combination antiretroviral therapy (cART), HIV-infected individuals are developing several non-AIDS-related comorbid conditions. Consequently, medical management of the HIV-infected population is increasingly complex, with a growing list of potential drug-drug interactions (DDIs). This article reviews some of the most relevant and emerging potential interactions between antiretroviral medications and other agents. The most common DDIs are those involving protease inhibitors or non-nucleoside reverse transcriptase inhibitors, which alter the cytochrome P450 enzyme system and/or drug transporters such as p-glycoprotein. Of note are the new agents for the treatment of chronic hepatitis C virus infection. These new classes of drugs and others drugs that are increasingly used in this patient population represent a significant challenge with regard to achieving the goals of effective HIV suppression and minimization of drug-related toxicities. Awareness of DDIs and a multidisciplinary approach are imperative in reaching these goals.

Original languageEnglish (US)
Pages (from-to)212-222
Number of pages11
JournalJoint Commission Journal on Quality and Patient Safety
Volume11
Issue number3
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Drug Monitoring
Drug Interactions
Pharmaceutical Preparations
HIV
Cytochrome P-450 Enzyme System
Reverse Transcriptase Inhibitors
Chronic Hepatitis C
Virus Diseases
Protease Inhibitors
Drug-Related Side Effects and Adverse Reactions
Hepacivirus
Population
Glycoproteins
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Drug interactions and antiretroviral drug monitoring. / Foy, Matthew; Sperati, C. John; Lucas, Gregory M.; Estrella, Michelle M.

In: Joint Commission Journal on Quality and Patient Safety, Vol. 11, No. 3, 01.09.2014, p. 212-222.

Research output: Contribution to journalArticle

Foy, Matthew ; Sperati, C. John ; Lucas, Gregory M. ; Estrella, Michelle M. / Drug interactions and antiretroviral drug monitoring. In: Joint Commission Journal on Quality and Patient Safety. 2014 ; Vol. 11, No. 3. pp. 212-222.
@article{2d5154379431452382da7d7280427a65,
title = "Drug interactions and antiretroviral drug monitoring",
abstract = "Owing to the improved longevity afforded by combination antiretroviral therapy (cART), HIV-infected individuals are developing several non-AIDS-related comorbid conditions. Consequently, medical management of the HIV-infected population is increasingly complex, with a growing list of potential drug-drug interactions (DDIs). This article reviews some of the most relevant and emerging potential interactions between antiretroviral medications and other agents. The most common DDIs are those involving protease inhibitors or non-nucleoside reverse transcriptase inhibitors, which alter the cytochrome P450 enzyme system and/or drug transporters such as p-glycoprotein. Of note are the new agents for the treatment of chronic hepatitis C virus infection. These new classes of drugs and others drugs that are increasingly used in this patient population represent a significant challenge with regard to achieving the goals of effective HIV suppression and minimization of drug-related toxicities. Awareness of DDIs and a multidisciplinary approach are imperative in reaching these goals.",
author = "Matthew Foy and Sperati, {C. John} and Lucas, {Gregory M.} and Estrella, {Michelle M.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1007/s11904-014-0212-1",
language = "English (US)",
volume = "11",
pages = "212--222",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Drug interactions and antiretroviral drug monitoring

AU - Foy, Matthew

AU - Sperati, C. John

AU - Lucas, Gregory M.

AU - Estrella, Michelle M.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Owing to the improved longevity afforded by combination antiretroviral therapy (cART), HIV-infected individuals are developing several non-AIDS-related comorbid conditions. Consequently, medical management of the HIV-infected population is increasingly complex, with a growing list of potential drug-drug interactions (DDIs). This article reviews some of the most relevant and emerging potential interactions between antiretroviral medications and other agents. The most common DDIs are those involving protease inhibitors or non-nucleoside reverse transcriptase inhibitors, which alter the cytochrome P450 enzyme system and/or drug transporters such as p-glycoprotein. Of note are the new agents for the treatment of chronic hepatitis C virus infection. These new classes of drugs and others drugs that are increasingly used in this patient population represent a significant challenge with regard to achieving the goals of effective HIV suppression and minimization of drug-related toxicities. Awareness of DDIs and a multidisciplinary approach are imperative in reaching these goals.

AB - Owing to the improved longevity afforded by combination antiretroviral therapy (cART), HIV-infected individuals are developing several non-AIDS-related comorbid conditions. Consequently, medical management of the HIV-infected population is increasingly complex, with a growing list of potential drug-drug interactions (DDIs). This article reviews some of the most relevant and emerging potential interactions between antiretroviral medications and other agents. The most common DDIs are those involving protease inhibitors or non-nucleoside reverse transcriptase inhibitors, which alter the cytochrome P450 enzyme system and/or drug transporters such as p-glycoprotein. Of note are the new agents for the treatment of chronic hepatitis C virus infection. These new classes of drugs and others drugs that are increasingly used in this patient population represent a significant challenge with regard to achieving the goals of effective HIV suppression and minimization of drug-related toxicities. Awareness of DDIs and a multidisciplinary approach are imperative in reaching these goals.

UR - http://www.scopus.com/inward/record.url?scp=84925548513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925548513&partnerID=8YFLogxK

U2 - 10.1007/s11904-014-0212-1

DO - 10.1007/s11904-014-0212-1

M3 - Article

C2 - 24950731

VL - 11

SP - 212

EP - 222

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 3

ER -